BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2000
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures. Operations are segmented into four geographic regions: United States, Europe, Japan, and Inter-Continental.

Key Financial Metrics

Note: Total Debt calculated as Commercial Paper ($399M) + Bank Obligations ($213M) + Long-term Debt ($570M).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4% to $679 million. U.S. revenues dropped 11% to $391 million, while international revenues increased 8% to $288 million.
• Product Mix Shift: Worldwide vascular sales decreased 6%, driven by a significant drop in U.S. coronary stent sales (NIR(R) stent) from $105 million to $63 million. Conversely, nonvascular sales increased 12%.
• Profitability: Despite lower sales, Net Income increased 6% to $106 million. Gross margin improved to 68.6% due to supply chain optimization and inventory management.
• Expense Management: Selling, general, and administrative (SG&A) expenses rose to $214 million (32% of sales) due to increased field sales force costs. Interest expense decreased significantly from $35 million to $21 million due to lower average debt balances.
• Liquidity: Working capital turned negative, with current liabilities exceeding current assets by $29 million. Cash and cash equivalents decreased by $8 million during the quarter.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Growth Expectations: Management expects 2000 sales growth to be below historical rates due to market volatility and the timing of FDA approvals for new stent platforms.
• Capital Needs: The company anticipates sufficient cash flow and borrowing capacity to meet needs through 2000. Estimated capital expenditures for the remainder of 2000 are $80 million.
• Supply Chain: Continued gross margin benefits are expected as manufacturing processes are addressed and historical inventories are sold.

Risks and Contingencies

• Supply Chain Dependency: The company relies on Medinol Ltd. for NIR(R) coronary stents. Delays or interruptions could adversely affect results. Inventory of these stents was $139 million at quarter-end.
• Legal Proceedings: The company is involved in extensive patent litigation with competitors including Advanced Cardiovascular Systems (ACS), Johnson & Johnson (Cordis/Ethicon), Medtronic, and Cook Inc. Potential exposure for litigation-related costs is estimated between $41 million and $51 million.
• Regulatory Investigations: The U.S. Department of Justice is investigating the voluntary recall of the NIR ON(R) Ranger(TM) with Sox(TM) coronary stent. The FTC is also investigating compliance with a Consent Order regarding intravascular ultrasound technology.
• Market Risks: Exposure to foreign currency fluctuations (hedging program in place) and interest rate changes on floating-rate debt.

Investor Verification Checklist

• Stent Sales Volatility: Verify the impact of the 40% drop in U.S. coronary stent sales on future revenue projections and the timeline for new FDA approvals.
• Medinol Supply Agreement: Review the terms of the supply agreement with Medinol Ltd. regarding the $139 million inventory and $26 million purchase commitment.
• Litigation Reserves: Monitor the $41 million litigation accrual and the status of key patent cases against ACS, Johnson & Johnson, and Medtronic.
• Regulatory Status: Track the outcome of the DOJ investigation regarding the 1998 stent recall and the FTC investigation.
• Debt Structure: Assess the reliance on commercial paper ($399 million) and revolving credit facilities ($201 million) given the negative working capital position.